Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 96 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption: Data From... June 15, 2022 Lung Adenocarcinoma with Mucinous Histology December 16, 2024 Why Have Thyroid Cancer Diagnoses Spiked for US Women? September 28, 2021 Making a startup out of a scientist April 26, 2023 Load more HOT NEWS Can Getting a Tattoo Cause Cancer? Cancer in My Community: Addressing Health Disparities in Brazil Outcomes From Second-Line Chemotherapy in Patients with Cholangiocarcinoma and FGFR2 Fusions Foodie Fridays: Watermelon Salad
